Massmutual Trust Co. FSB ADV Acquires 217 Shares of Becton, Dickinson and Company (NYSE:BDX)

Massmutual Trust Co. FSB ADV grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 56.2% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 603 shares of the medical instruments supplier’s stock after buying an additional 217 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Becton, Dickinson and Company were worth $141,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of BDX. Ridgewood Investments LLC increased its position in shares of Becton, Dickinson and Company by 1.5% during the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock valued at $731,000 after acquiring an additional 43 shares in the last quarter. Key Client Fiduciary Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 2.6% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after buying an additional 43 shares during the last quarter. CWM LLC increased its holdings in shares of Becton, Dickinson and Company by 0.7% in the 4th quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after buying an additional 46 shares during the last quarter. Edge Capital Group LLC grew its holdings in Becton, Dickinson and Company by 3.1% during the 4th quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock valued at $384,000 after purchasing an additional 48 shares during the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. grew its holdings in Becton, Dickinson and Company by 1.3% during the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,951 shares of the medical instruments supplier’s stock valued at $963,000 after purchasing an additional 49 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 3,300 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total transaction of $781,209.00. Following the completion of the sale, the executive vice president now owns 11,308 shares of the company’s stock, valued at approximately $2,676,942.84. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the completion of the sale, the executive vice president now owns 11,308 shares of the company’s stock, valued at $2,676,942.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The disclosure for this sale can be found here. Insiders have sold a total of 6,900 shares of company stock worth $1,634,112 in the last three months. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Performance

BDX stock traded down $5.97 on Monday, hitting $235.90. The company’s stock had a trading volume of 1,474,243 shares, compared to its average volume of 1,461,122. The firm has a 50 day moving average of $232.90 and a two-hundred day moving average of $236.30. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $284.48. The stock has a market cap of $68.18 billion, a price-to-earnings ratio of 52.34, a price-to-earnings-growth ratio of 2.06 and a beta of 0.42. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the prior year, the company posted $2.96 EPS. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. Equities analysts predict that Becton, Dickinson and Company will post 13.06 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Evercore ISI decreased their target price on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Barclays upped their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective on the stock. Finally, Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $279.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.